The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Our Products

We have developed an extensive range of products for infectious disease research and development, and particularly for use in the manufacturing of immunoassays in the IVD sector, and for vaccine research in the biopharmaceutical sector.

The Native Antigen Company produces infectious disease antigens from a range of established and emerging viral, bacterial and protozoal diseases. We provide both native and recombinant antigens produced using our VirtuE, mammalian expression system. Our antigens are suitable for use in vaccine R&D, as components for serological based diagnostic assays and for fundamental research into infectious diseases. We have decades of experience in providing bulk and customised formats for industry.

The Native Antigen Company provides a range of virus-like particles (VLPs), expressed in our VirtuE, mammalian expression system. Comprised of outer viral proteins, VLPs closely representative viral antigens in vivo and while, lacking genetic material. As an emerging vaccine technology, VLPs are ideal in elicting safe and eiptope-specific immune responses.

We are working to develop the world’s most extensive range of antibodies for infectious disease targets, with a rapidly expanding range. Our range includes a unique panel of highly specific antibodies for flavivirus NS1 proteins, including serotype-specific reagents for Dengue and human chimeric antibodies to Zika NS1. We also offer a range of antibody pairs optimised for Capture and Detection, self pairing antibodies (Self Pair) and those which have been shown to pair but have not been fully optimised (Pair). 

Human cell surface receptors (CSRs) are key proteins in the development of novel therapeutics. To support research in this area, we have produced a panel of recombinant human CSRs that are known to mediate virus entry. In many cases, we also provide the viral proteins that bind the corresponding CSR for molecular interaction studies.

The Native Antigen Company offers a range of highly purified bacterial toxins that are widely used in cell biology applications, studying pathways in diseases such as cardiovascular disorders, cancer and diabetes. Pertussis toxin acts to inhibit the ability of G proteins to function in signalling pathways, whilst Diphtheria toxin inhibits protein synthesis by catalyzing ADP-ribosylation of eukaryotic aminoacyltransferase. In contrast Clostridium difficile toxins A and B act to destroy the actin cytoskeleton of cells by inactivation of Rho family GTPases.  Each of our toxins are purified directly from cultured bacteria, and undergo several purification steps to produce highly pure reagents.  The reagents are suitable for use in cellular assays, as antigens for antibody production, and also for use in IVD assays.

The Native Antigen Company offers a range of viral and bacterial research-use immunoassays. Our immunoassays for Zika virus are the most specific and sensitive available on the market. We have assays to detect the serological response to infection, and also to measure levels of Zika NS1 protein during infection. Further immunoassays are in development, so please check back regularly for updates.

The Native Antigen Company now offers an expanding range of antigens, antibodies and immunoassays for companion animals and livestock.

The Native Antigen Company offers a range of protein conjugation kits for AP, biotin, FITC, HRP and RE, as well as Legionella-specific and Gram-negative-specific fluorescence labelling kits.

We offer a range of accessory reagents to support the use of our antigens and antibodies, including disease-state donor sera, buffers, secondary antibodies and isotype control antibodies.

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 5 =